These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33137335)

  • 1. Clinical and immunological follow-up of very long-term kidney transplant recipients treated with calcineurin inhibitors indicates dual phenotypes.
    Dujardin A; Chesneau M; Dubois F; Danger R; Bui L; Kerleau C; Guérif P; Brouard S; Dantal J
    Kidney Int; 2021 Jun; 99(6):1418-1429. PubMed ID: 33137335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic Signature of the CD24
    Bigot J; Pilon C; Matignon M; Grondin C; Leibler C; Aissat A; Pirenne F; Cohen JL; Grimbert P
    Am J Transplant; 2016 Dec; 16(12):3430-3442. PubMed ID: 27273606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological monitoring of the efficacy of extracorporeal photopheresis for prevention of kidney transplant rejection].
    Faenko AP; Chuksina YY; Zulkarnayev AB; Fedulkina VA; Vatazin AV; Kantaria RO
    Urologiia; 2020 Sep; (4):73-78. PubMed ID: 32897018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients.
    Niu Q; Mendoza Rojas A; Dieterich M; Roelen DL; Clahsen-van Groningen MC; Wang L; van Gelder T; Hesselink DA; van Besouw NM; Baan CC
    Front Immunol; 2020; 11():1972. PubMed ID: 32983131
    [No Abstract]   [Full Text] [Related]  

  • 5. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
    Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
    Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-regulatory cells in chronic rejection versus stable grafts.
    Al-Wedaie F; Farid E; Tabbara K; El-Agroudy AE; Al-Ghareeb SM
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():170-6. PubMed ID: 25894149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
    Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.
    Del Bello A; Marion O; Milongo D; Rostaing L; Kamar N
    Expert Rev Clin Pharmacol; 2016; 9(2):215-27. PubMed ID: 26691282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch from calcineurin inhibitors to belatacept in kidney transplant patients with chronic-active antibody mediated rejection results in lower decline in kidney function at three years.
    de Nattes T; François A; Candon S; Etienne I; Laurent C; Matignon M; Morel A; Noble J; Planchais M; Guerrot D; Bertrand D
    J Nephrol; 2021 Dec; 34(6):2159-2162. PubMed ID: 34181198
    [No Abstract]   [Full Text] [Related]  

  • 13. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral phenotype and gene expression profiles of combined liver-kidney transplant patients.
    Dumontet E; Danger R; Vagefi PA; Londoño MC; Pallier A; Lozano JJ; Giral M; Degauque N; Soulillou JP; Martínez-Llordella M; Lee H; Latournerie M; Boudjema K; Dulong J; Tarte K; Sanchez-Fueyo A; Feng S; Brouard S; Conchon S
    Liver Int; 2016 Mar; 36(3):401-9. PubMed ID: 26193627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
    Aiello FB; Furian L; Marino S; Marchini F; Cardillo M; De Fazio N; Rigotti P; Valente M
    Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients.
    Latorre I; Esteve-Sole A; Redondo D; Giest S; Argilaguet J; Alvarez S; Peligero C; Forstmann I; Crespo M; Pascual J; Meyerhans A
    Transpl Immunol; 2016 Mar; 35():1-6. PubMed ID: 26836476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.